We are live on ! Find out more
Jacobs Levy Equity Management

Jacobs Levy Equity Management Portfolio holdings

AUM $23.8B
1-Year Est. Return 25.4%
This Fund
S&P 500
This Quarter Est. Return
+7.34%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$7.05B
AUM Growth
+$688M
Cap. Flow
+$306M
Cap. Flow %
4.35%
Top 10 Hldgs %
15.99%
Holding
1,149
New
136
Increased
453
Reduced
359
Closed
174

Top Buys

Rank Stock Value
1
GOOG icon
Alphabet (Google) Class C
GOOG
+$40.4M
2
AMZN icon
Amazon
AMZN
+$35M
3
TJX icon
TJX Companies
TJX
+$34.6M
4
PSX icon
Phillips 66
PSX
+$33.1M
5
MA icon
Mastercard
MA
+$32.3M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$31.7M
2
CI icon
Cigna
CI
+$27.3M
3
META icon
Meta Platforms (Facebook)
META
+$21.6M
4
JPM icon
JPMorgan Chase
JPM
+$21M
5
MRVL icon
Marvell Technology
MRVL
+$20.2M

Sector Composition

Rank Sector Weight
1 Technology 20.29%
2 Financials 17.18%
3 Consumer Discretionary 12.24%
4 Industrials 11.66%
5 Healthcare 10.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TCON
951
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$149K ﹤0.01%
364
-47
-11% -$21.8K
TPST icon
952
Tempest Therapeutics
TPST
$14.8M
$140K ﹤0.01%
66
IDT icon
953
IDT Corp
IDT
$1.6B
$139K ﹤0.01%
26,100
AGEN
954
Agenus
AGEN
$249M
$135K ﹤0.01%
3,210
-255
-7% -$10K
OTIC
955
DELISTED
Otonomy, Inc.
OTIC
$135K ﹤0.01%
49,211
-52,724
-52% -$169K
VIRX
956
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$134K ﹤0.01%
1,915
-825
-30% -$62.6K
SURF
957
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$134K ﹤0.01%
+12,234
New +$143K
ADXS
958
DELISTED
Advaxis Inc
ADXS
$130K ﹤0.01%
+9,190
New +$179K
ALSK
959
DELISTED
Alaska Communications Systems
ALSK
$129K ﹤0.01%
78,557
-17,684
-18% -$30.6K
RNTX
960
Rein Therapeutics
RNTX
$67.7M
$126K ﹤0.01%
+2,289
New +$154K
IRIX icon
961
IRIDEX
IRIX
$15.5M
$125K ﹤0.01%
19,763
-4,383
-18% -$32.6K
TLRA
962
DELISTED
Telaria, Inc.
TLRA
$124K ﹤0.01%
32,801
+9,813
+43% +$38K
NOVN
963
DELISTED
Novan, Inc. Common Stock
NOVN
$123K ﹤0.01%
4,413
FTD
964
DELISTED
FTD Companies, Inc. Common Stock
FTD
$95K ﹤0.01%
+36,207
New +$133K
XFOR icon
965
X4 Pharmaceuticals
XFOR
$363M
$94K ﹤0.01%
323
+259
+405% +$110K
PTX
966
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$84K ﹤0.01%
87,643
LPCN icon
967
Lipocine
LPCN
$17.1M
$83K ﹤0.01%
3,532
-286
-7% -$7.03K
SB icon
968
Safe Bulkers
SB
$781M
$61K ﹤0.01%
21,212
ASPN icon
969
Aspen Aerogels
ASPN
$387M
$50K ﹤0.01%
10,953
-11,147
-50% -$54.3K
GNMX
970
DELISTED
Aevi Genomic Medicine Inc
GNMX
$45K ﹤0.01%
36,690
-83,929
-70% -$93.8K
KODK icon
971
Kodak
KODK
$806M
$42K ﹤0.01%
13,465
-64,554
-83% -$211K
ACTG icon
972
Acacia Research
ACTG
$450M
$36K ﹤0.01%
11,200
-8,454
-43% -$31.4K
HIND
973
Vyome Holdings
HIND
$14.5M
0
ATNM icon
974
Actinium Pharmaceuticals
ATNM
$27M
$21K ﹤0.01%
953
AEO icon
975
American Eagle Outfitters
AEO
$2.85B
-41,700
Closed -$970K

Similar funds

Jacobs Levy Equity Management's Q3 2018 Portfolio in Review

As of Q3 2018, Jacobs Levy Equity Management held 1,149 positions worth $7.05B, up 11% from $6.36B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

Jacobs Levy Equity Management deployed $306M of net new capital in Q3 2018, opening 136 new positions and adding to 453 existing holdings. Its largest new stake was TJX Companies: 673,440 shares worth $37.7M.

By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Consumer Discretionary.

On the sell side, the largest reduction was Eli Lilly, an estimated $31.7M trimmed.

  • Jacobs Levy Equity Management's largest Q3 2018 buy was TJX Companies: 673,440 shares worth $37.7M.
  • Jacobs Levy Equity Management added most to Alphabet (Google) Class C in Q3 2018, an estimated $40.4M increase.
  • Jacobs Levy Equity Management's biggest Q3 2018 reduction was Eli Lilly, cutting an estimated $31.7M.
  • Jacobs Levy Equity Management fully exited Dun & Bradstreet in Q3 2018, selling an estimated $17.2M.
  • Jacobs Levy Equity Management's ten largest holdings make up 16% of its $7.05B portfolio in Q3 2018.
  • Jacobs Levy Equity Management opened 136 new positions and closed 174 in Q3 2018.
  • Jacobs Levy Equity Management's portfolio value rose 11% quarter-over-quarter to $7.05B.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2018, filed 14 Nov 2018.